Tags

Type your tag names separated by a space and hit enter

Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland.
J Pediatric Infect Dis Soc. 2017 Nov 24; 6(4):317-323.JP

Abstract

Key points

The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also.

Background

Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up.

Methods

Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as "cases" and rotavirus-negative children as "controls." Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001-2006) and post-NIP seasons (2009-2013).

Results

The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%-98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons.

Conclusions

Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children.

Authors+Show Affiliations

Vaccine Research Center, School of Medicine, University of Tampere.Vaccine Research Center, School of Medicine, University of Tampere.PEDEGO Research Unit, University of Oulu, Finland.PEDEGO Research Unit, University of Oulu, Finland.Vaccine Research Center, School of Medicine, University of Tampere.Epidemiology Department, Sanofi Pasteur-MSD, Lyon.Epidemiology Department, Sanofi Pasteur-MSD, Lyon.IRD UMR 216, Faculté de Pharmacie, Université Paris Descartes, France.Epidemiology Department, Sanofi Pasteur-MSD, Lyon.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27760800

Citation

Hemming-Harlo, Maria, et al. "Sustained High Effectiveness of RotaTeq On Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland." Journal of the Pediatric Infectious Diseases Society, vol. 6, no. 4, 2017, pp. 317-323.
Hemming-Harlo M, Vesikari T, Uhari M, et al. Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland. J Pediatric Infect Dis Soc. 2017;6(4):317-323.
Hemming-Harlo, M., Vesikari, T., Uhari, M., Renko, M., Salminen, M., Torcel-Pagnon, L., Hartwig, S., Simondon, F., & Bricout, H. (2017). Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland. Journal of the Pediatric Infectious Diseases Society, 6(4), 317-323. https://doi.org/10.1093/jpids/piw061
Hemming-Harlo M, et al. Sustained High Effectiveness of RotaTeq On Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland. J Pediatric Infect Dis Soc. 2017 Nov 24;6(4):317-323. PubMed PMID: 27760800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland. AU - Hemming-Harlo,Maria, AU - Vesikari,Timo, AU - Uhari,Matti, AU - Renko,Marjo, AU - Salminen,Marjo, AU - Torcel-Pagnon,Laurence, AU - Hartwig,Susanne, AU - Simondon,Francois, AU - Bricout,Hélène, PY - 2016/03/31/received PY - 2016/08/25/accepted PY - 2016/10/21/pubmed PY - 2018/7/4/medline PY - 2016/10/21/entrez KW - RotaTeq KW - effectiveness KW - gastroenteritis KW - impact KW - rotavirus KW - vaccine SP - 317 EP - 323 JF - Journal of the Pediatric Infectious Diseases Society JO - J Pediatric Infect Dis Soc VL - 6 IS - 4 N2 - Key points: The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also. Background: Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up. Methods: Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as "cases" and rotavirus-negative children as "controls." Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001-2006) and post-NIP seasons (2009-2013). Results: The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%-98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons. Conclusions: Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children. SN - 2048-7207 UR - https://www.unboundmedicine.com/medline/citation/27760800/Sustained_High_Effectiveness_of_RotaTeq_on_Hospitalizations_Attributable_to_Rotavirus_Associated_Gastroenteritis_During_4_Years_in_Finland_ L2 - https://academic.oup.com/jpids/article-lookup/doi/10.1093/jpids/piw061 DB - PRIME DP - Unbound Medicine ER -